LOGIN
Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19
March 2021
Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial
Eur J Integr Med. 2021 01-Feb;():. 10.1016/j.eujim.2021.101305Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty patients with severe COVID-19 were randomized to receive routine care plus intravenous Xuebijing injection (n=30) or routine care alone (n=30) for the suppression of inflammatory response and management of symptoms. The primary outcome of interest was peripheral blood lymphocyte and interleukin (IL)-6 levels which were measured at 1, 7 and 14 days follow-up. Secondary outcomes of interest in...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.